Trials / Completed
CompletedNCT00471211
Study Evaluating the Safety, Tolerability and Efficacy of PBT2 in Patients With Early Alzheimer's Disease
A 12-Week, Randomised, Double-Blind, Placebo-Controlled, Parallel Three-Group Study to Assess the Safety, Tolerability and Efficacy of Two Dose Levels of PBT2 to Slow Progression of Disease in Patients With Early Alzheimer's Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- Sponsor
- Prana Biotechnology Limited · Industry
- Sex
- All
- Age
- 56 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to determine the safety, tolerability and efficacy of 2 doses of PBT2 administered for 12 weeks compared to placebo in patients with early Alzheimer's disease treated with an acetylcholinesterase inhibitor.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PBT2 |
Timeline
- Start date
- 2006-12-01
- Primary completion
- 2007-12-01
- Completion
- 2007-12-01
- First posted
- 2007-05-09
- Last updated
- 2008-01-16
Locations
15 sites across 2 countries: Australia, Sweden
Source: ClinicalTrials.gov record NCT00471211. Inclusion in this directory is not an endorsement.